GoTrust’s Idem Key Is the First USB/NFC Security Key, Working Across All User Devices, to Be Granted a FIDO2 Security Level 2
23.3.2021 18:00:00 EET | Business Wire | Press release
Today, GoTrustID Inc. (GoTrust) announced that their Idem Keys have been upgraded from FIDO2 Security Level 1 to Security Level 2 certification for passwordless login for devices, applications and cloud services. The Idem Keys have USB-A, USB-C and NFC interfaces. All GoTrust Idem Keys work with Windows, MAC, Chromebook, iOS and Android phones. The Idem Key can also be used for physical access.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210323005056/en/
GoTrust FIDO2 Security Level 2 Idem Key, mojeID Identity service provided by CZ.NIC (Photo: Business Wire)
An eager customer for the GoTrust Level 2 Idem Key is the mojeID Identity service provided by CZ.NIC. Authorized by the Czech Ministry of the Interior, mojeID is able to access online government services. There are 700,000 users registered with mojeID today.
Going forward, to access more sensitive sites that require the highest level of assurance (LoA) such as opening a bank account or potentially in the future transferring property in property registry, mojeID users will need to use a FIDO2 Security Level 2 token with a security element certified by FIPS/CC. The only such token on the market today that works across every user device is the GoTrust Idem Key. “We were delighted to find exactly the token we required to get LoA High accreditation,” commented Ondřej Filip, CEO at CZ.NIC. “Cooperation with GoTrustID Inc. has been perfect since the beginning and we really admire their decision to go the through L2 certification process.”
Shipment of Idem Keys to CZ.NIC has already started and is expected to grow rapidly as the demand for the highest LoA services increases.
About GoTrustID Inc.
GoTrustID Inc. (GoTrust) is the pioneer company providing a passwordless multi-factor authentication (MFA) platform for an employee’s everyday items: phone, a USB Key or their smart badge. Our mission is to make simple & secure login anywhere and anytime. With every authenticator and server certified by FIDO, GoTrust Authentication Platform makes every employee become their own ID, having effortless login to their computer, corporate systems and cloud services. GoTrustID has twenty-four international patents granted, including six US patents.
GoTrust FIDO2 Security Level 2 Idem Key is available on Amazon. https://www.amazon.com/dp/B07YTL3Q1Y?ref=myi_title_dp
About CZ.NIC
CZ.NIC, z. s. p. o., is an interest association of legal entities, founded in 1998. The association currently has 117 members. One key activity of the association is the operation of the domain name registry for the .CZ domain. The association is now intensively working on development of the mojeID service supporting new technologies and projects beneficial to the Internet infrastructure in the Czech Republic.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210323005056/en/
Contact information
Kevin Lee
+82.10.9232.5467
kevin.lee@gotrustid.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Compass Pathways Working with U.S. Department of Veterans Affairs for Investigational Study of Psilocybin6.8.2026 13:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today it is working with the U.S. Department of Verterans Affairs (VA) on a multi-site randomized controlled clinical trial. The study will evaluate the safety and efficacy of COMP360 psilocybin in the treatment of treatment-resistant depression (TRD) in veterans, including those with concurrent post-traumatic stress disorder (PTSD). The trial, titled "Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression," or PIVOT, reflects VA’s commitment to pursuing innovative solutions for veterans who have not responded to existing treatments. Compass will donate the study drug - COMP360, a synthetic, proprietary pharmaceutical-grade formulation of psilocybin optimized for stability and purity. Compass will support the education and training of the investigators and their training team through the provision of training
Great Britain Leads Europe’s FMCG Inflation as NIQ Launches New Inflation Barometer6.8.2026 10:00:00 EEST | Press release
NIQ (NYSE: NIQ) today launches its new EU5 FMCG Inflation Barometer - a monthly tracker across five Western Europe markets – France, Great Britain, Germany, Italy and Spain – designed to help retailers, manufacturers and the media understand how inflation is evolving across Europe’s largest grocery markets and how shoppers are responding. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806579111/en/ EU5 CPG Inflation slows to +1.1% The first edition of the Barometer reveals that while inflation across Europe’s FMCG sector remains relatively contained overall, significant differences persist between countries. Key findings include: Great Britain recorded the highest FMCG inflation across the EU5 at +2.3%1, above the European average of +1.1%. France and Italy reported the lowest inflation at -0.4% and +0.6% retrospectively, highlighting the uneven inflationary landscape across Europe's major economies. The monthly Barometer
NTT DOCOMO BUSINESS and Chile’s State-owned Copper Company CODELCO Launch a Study and Proof of Concept Aimed at Improving the Efficiency of Remote Copper Mine Operations Using IOWN ® APN6.8.2026 07:30:00 EEST | Press release
NTT DOCOMO BUSINESS, Inc. (formerly NTT Communications Corporation) has launched a study and proof of concept jointly with Corporación Nacional del Cobre de Chile (CODELCO) to progress remote operations at CODELCO’s copper mines using an IOWN® All-Photonics Network (APN).1 This initiative is part of a research project commissioned by Japan’s Ministry of Internal Affairs and Communications.2 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806845222/en/ Conceptual Diagram of the Demonstration To address operational challenges faced by CODELCO’s copper mines, the initiative will connect a copper mine and a remote operations center—approximately 1,500 km apart—via an IOWN APN. It will assess the feasibility of remotely operating heavy machinery using high-capacity, low-latency communication links, enhancing monitoring operations through high-definition video, and implementing a remote operations model. 1. Background Chile is o
FPT Named an OpenAI Select Partner6.8.2026 03:00:00 EEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 01:10:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of ORZEYFUL marks a new chapter for the narcolepsy type 1 community, as we introduce an entirely new class of medicine that will potentially redefine how this disease is managed and howpeople feel on treatment,” said Julie Kim, president and chief executive officer of Takeda. “We are proud to have discovered and developed this orexin treatment innovation and will bring it to adults living with NT1 as quickly as possible.” NT1 is a rare, chronic neurological disease d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom